Airway abundance of Haemophilus influenzae predicts response to azithromycin in adults with persistent uncontrolled asthma

AMAZES Investigators Group

Research output: Contribution to journalLetterpeer-review

6 Citations (Scopus)

Abstract

Long-term azithromycin treatment reduced exacerbations in adults with persistent symptomatic asthma in the AMAZES trial (Australian and New Zealand Clinical Trials Registry (ANZCTR), number 12609000197235) [1]. However, response to treatment was variable between participants and the characteristics of those who experience most clinical benefit have not been determined. The inability to define a specific population who are more responsive limits the ability to personalise this therapy, which is the goal for airways disease management [2]. With recent studies identifying airway Haemophilus influenzae colonisation as a candidate marker for asthma subgrouping [3, 4], we assessed whether H. influenzae abundance, measured using quantitative PCR (qPCR) [5, 6], predicted the ability of azithromycin therapy to reduce the incidence of acute asthma exacerbations.
Original languageEnglish
Article number2000194
Number of pages2
JournalEuropean Respiratory Journal
Volume56
Issue number4
DOIs
Publication statusPublished - 1 Oct 2020

Keywords

  • azithromycin
  • asthma
  • airways disease management

Fingerprint Dive into the research topics of 'Airway abundance of Haemophilus influenzae predicts response to azithromycin in adults with persistent uncontrolled asthma'. Together they form a unique fingerprint.

Cite this